Qualaquin

(quinine)

ApprovedSmall molecule

BBiomed Industries, Inc.

Qualaquin is one of 76 small molecule programs targeting Ototoxicity. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

OtotoxicityActive, not recruiting

MalariaActive, not recruiting

Chronic PainActive, not recruiting

OtotoxicityApproved

Active, not recruiting

MalariaPhase 2

Active, not recruiting

Chronic PainPhase 2

Active, not recruiting

Competition

Competitive Landscape

479 competitors in Malaria

#DrugCompanyPhaseTrials

Qualaquin

BBiomed Industries, Inc.

Approved

8 2

Biltricide

Bayer

Preclinical

1 3

Stelara

Johnson & Johnson

Preclinical

—4

Hydroxychloroquine Sulfate

Novartis

Preclinical

—5

Iron

WWatson Pharmaceuticals

Preclinical

1 6

IV LBH589

Novartis

Preclinical

1 7

IV Ceftriaxone

RRESnTEC, Institute of Research

Preclinical

1 8

Mefloquine Plus Artesunate

Medicines for Malaria Venture

Preclinical

1 9

RTS,S/AS01E

GSK

Preclinical

4 10

Piperaquine

UUniversity of Oxford

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Malaria8 trials

Parenteral Artesunate Compared to Quinine as a Cause of Late Anaemia in African Children With Malaria

Completed·UUniversity of Oxford·Phase 4·NCT02092766·217 enrolled

Intravenous Artesunate and Malaria

Unknown status·UUniversity of Khartoum·Phase 4·NCT01805232·80 enrolled

Superiority of ArTiMist Versus Quinine in Children With Severe Malaria

Completed·PProto Pharma Ltd·Phase 3·NCT01258049·151 enrolled

Show 5 more trials

Azithromycin Combination Therapy for Malaria

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00299208·120 enrolled

A Trial of the Efficacy of Artesunate and Three Quinine Regimens in the Treatment of Severe Malaria in Children at the Ebolowa Regional Hospital - Cameroon

Completed·UUniversity of Yaounde 1·Phase 3·NCT02563704·238 enrolled

Antimalaria Drugs Susceptibility Testing for an Effective Management of Infected Patients in Sub-Sahara Africa

Completed·—·Phase 3·NCT02974348·300 enrolled

Bio-availability of Rectal Artesunate in Children With Severe Falciparum Malaria

Completed·UUniversity of Oxford·Phase 2·NCT02492178·82 enrolled

Effectiveness of Oral Quinine and Artemether-Lumefantrine in the Treatment of Uncomplicated Malaria in Ugandan Children

Unknown status·MMakerere University·Phase 4·NCT00540202·302 enrolled

Interaction2 trials

Interactions Between Intravenous Cocaine and Acetazolamide or Quinine

Completed·NNational Institute on Drug Abuse (NIDA)·Phase 1·NCT01851473·14 enrolled

Drug - Drug Interaction Study Between Quinine Sulfate and Theophylline

Completed·MMutual Pharmaceutical Company, Inc.·Phase 1·NCT00779259·24 enrolled

Ototoxicity1 trial

Ototoxicity of Artemether / Lumefantrine (Coartem) and Other Antimalarials

Completed·JJimma University·Phase 4·NCT00451139

Pregnancy1 trial

Quinine vs. Artemether/Lumefantrine in Uncomplicated Malaria During Pregnancy

Completed·EEpicentre·Phase 4·NCT00495508·300 enrolled

Children1 trial

Efficacy of ArTiMist™ in Children

Completed·PProto Pharma Ltd·Phase 2·NCT01047436·31 enrolled

1 more indication

Chronic pain1 trial

Evaluation of a Compliance Marker in Prescription Opioid Abusers With Chronic Pain

Withdrawn·GGeorgetown University·Phase 2·NCT02276989

Regulatory

FDA Approval Timeline[4]

Aug 12, 2005

QUALAQUIN

NDA NDA021799

Sources

References

[1]
ClinicalTrials.gov — 14 trial records for quinine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — quinine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for quinine. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA021799). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Biomed Industries, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: BBiomed Industries, Inc.

Qualaquin

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Malaria8 trials

Interaction2 trials

Ototoxicity1 trial

Pregnancy1 trial

Children1 trial

Chronic pain1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News